Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer

Chung, 2019, Prospective comprehensive genomic profiling of primary and metastatic prostate tumors, JCO Precis Oncol, 3, e1800283 Graf, 2022, Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer, JAMA Netw Open, 5, e225394, 10.1001/jamanetworkopen.2022.5394 Abida, 2019, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade, JAMA Oncol, 5, 471, 10.1001/jamaoncol.2018.5801 Zurita, 2022, Genomic biomarkers and genome-wide loss-of-heterozygosity scores in metastatic prostate cancer following progression on androgen-targeting therapies, JCO Precis Oncol, 6, e2200195, 10.1200/PO.22.00195 Singal, 2019, Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database, JAMA, 321, 1391, 10.1001/jama.2019.3241 Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, 9, 34, 10.1186/s13073-017-0424-2 Trabucco, 2019, A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability–high cases in 67,000 patient samples, J Mol Diagn, 21, 1053, 10.1016/j.jmoldx.2019.06.011 Kensler, 2022, The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer, NPJ Precis Oncol, 6, 39, 10.1038/s41698-022-00284-6 Sokol, 2022, PARP inhibitor insensitivity to BRCA1/2 monoallelic mutations in microsatellite instability-high cancers, JCO Precis Oncol, 6, e2100531, 10.1200/PO.21.00531